Phaseline

Companies › Grand Theravac Life Sciences (Nanjing)

Grand Theravac Life Sciences (Nanjing): clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TVAX-008–Phase 2Chronic Hepatitis B Virus; HBV InfectionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07190742TVAX-008Phase 2Chronic Hepatitis B VirusInfectious diseaseOct 2024
NCT07179653TVAX-008Phase 2HBV InfectionInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.